CN101374537B - 干细胞的mntf分化和生长 - Google Patents

干细胞的mntf分化和生长 Download PDF

Info

Publication number
CN101374537B
CN101374537B CN200680041827.0A CN200680041827A CN101374537B CN 101374537 B CN101374537 B CN 101374537B CN 200680041827 A CN200680041827 A CN 200680041827A CN 101374537 B CN101374537 B CN 101374537B
Authority
CN
China
Prior art keywords
mntf
cell
cells
differentiation
stem cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200680041827.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN101374537A (zh
Inventor
D·M·德施潘德
D·A·科尔
P-Y·D·寇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genervon Biopharmaceuticals LLC
Original Assignee
Genervon Biopharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genervon Biopharmaceuticals LLC filed Critical Genervon Biopharmaceuticals LLC
Publication of CN101374537A publication Critical patent/CN101374537A/zh
Application granted granted Critical
Publication of CN101374537B publication Critical patent/CN101374537B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN200680041827.0A 2005-11-10 2006-11-10 干细胞的mntf分化和生长 Expired - Fee Related CN101374537B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US73570205P 2005-11-10 2005-11-10
US60/735,702 2005-11-10
US84176606P 2006-09-01 2006-09-01
US60/841,766 2006-09-01
US85802206P 2006-11-10 2006-11-10
US60/858,022 2006-11-10
PCT/US2006/043874 WO2007058982A2 (en) 2005-11-10 2006-11-10 Mntf differentiation and growth of stem cells

Publications (2)

Publication Number Publication Date
CN101374537A CN101374537A (zh) 2009-02-25
CN101374537B true CN101374537B (zh) 2016-04-20

Family

ID=38049179

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200680041827.0A Expired - Fee Related CN101374537B (zh) 2005-11-10 2006-11-10 干细胞的mntf分化和生长

Country Status (7)

Country Link
US (1) US8986676B2 (https=)
EP (1) EP1965826B1 (https=)
JP (2) JP5270362B2 (https=)
CN (1) CN101374537B (https=)
AU (1) AU2006315668B2 (https=)
CA (1) CA2626728A1 (https=)
WO (1) WO2007058982A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2028268A1 (en) 2007-08-20 2009-02-25 Université Libre De Bruxelles Generation of neuronal cells from pluripotent stem cells
ES2569552T3 (es) * 2008-02-21 2016-05-11 Genervon Biopharmaceuticals Llc Composiciones de péptido de MNTF y métodos de uso
US20120142005A1 (en) * 2009-05-26 2012-06-07 Takeda Pharmaceutical Company Limited Method for screening of regenerative medicine
WO2013025963A2 (en) 2011-08-17 2013-02-21 President And Fellows Of Harvard College Conversion of somatic cells into functional spinal motor neurons, and methods and uses thereof
PT2773748T (pt) * 2011-11-04 2020-03-26 Memorial Sloan Kettering Cancer Center Neurónios dopaminérgicos (da) do mesencéfalo para enxerto
CN104073468B (zh) * 2014-07-16 2016-04-27 栾佐 获得人源OPCs的方法和OPCs培养基
US11427808B2 (en) 2014-11-14 2022-08-30 Regenesis Science Co., Ltd. Method for serum-free culture of chondrocytes and serum-free culture medium
WO2016210123A1 (en) 2015-06-26 2016-12-29 Genervon Biopharmaceuticals, LLC Methods of using gm604 in modulating als disease biomarkers leading to prognosis and therapeutic treatment for als disease
WO2018119018A1 (en) * 2016-12-23 2018-06-28 Genervon Biopharmaceuticals, LLC Methods of using gm6 in diagnosing and treating alzheimer's disease
US12364985B2 (en) * 2018-05-11 2025-07-22 Georgia Tech Research Corporation Systems and methods for electronic surface antigen expression analysis using magnetophoresis
CN118853569B (zh) * 2024-09-29 2025-03-04 星奕昂(上海)生物科技有限公司 一种拟胚体消化液及其在分离造血干细胞中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003044175A2 (en) * 2001-11-20 2003-05-30 Genervon Biopharmaceuticals Llc Methods and use of motoneuronotropic factors
WO2004065410A2 (en) * 2003-01-21 2004-08-05 Genervon Biopharmaceuticals Llc Mntf peptides and compositions and methods of use
WO2005047487A2 (en) * 2003-11-07 2005-05-26 Genervon Biopharmaceuticals Llc Motoneuronotrophic factor gene sequences

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US6309877B1 (en) 1996-09-27 2001-10-30 Km Biotech, Inc. Polynucleotides encoding motoneuronotrophic factors
US6300117B1 (en) 1997-09-15 2001-10-09 Genencor International, Inc. Proteases from gram-positive organisms
JP5943533B2 (ja) 2000-05-17 2016-07-06 アステリアス バイオセラピューティクス インコーポレイテッド 神経前駆細胞の集団
US7390659B2 (en) * 2002-07-16 2008-06-24 The Trustees Of Columbia University In The City Of New York Methods for inducing differentiation of embryonic stem cells and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003044175A2 (en) * 2001-11-20 2003-05-30 Genervon Biopharmaceuticals Llc Methods and use of motoneuronotropic factors
WO2004065410A2 (en) * 2003-01-21 2004-08-05 Genervon Biopharmaceuticals Llc Mntf peptides and compositions and methods of use
WO2005047487A2 (en) * 2003-11-07 2005-05-26 Genervon Biopharmaceuticals Llc Motoneuronotrophic factor gene sequences

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bain et al..Embryonic stem cells express neuronal properies in vitro.《Developmental Biology》.1995,第168卷(第2期), *

Also Published As

Publication number Publication date
JP5270362B2 (ja) 2013-08-21
JP2009515891A (ja) 2009-04-16
AU2006315668A1 (en) 2007-05-24
CN101374537A (zh) 2009-02-25
US20090117085A1 (en) 2009-05-07
JP2013177388A (ja) 2013-09-09
AU2006315668B2 (en) 2013-06-20
EP1965826B1 (en) 2014-12-31
WO2007058982A3 (en) 2008-09-25
HK1125824A1 (zh) 2009-08-21
EP1965826A4 (en) 2010-08-25
EP1965826A2 (en) 2008-09-10
US8986676B2 (en) 2015-03-24
CA2626728A1 (en) 2007-05-24
WO2007058982A2 (en) 2007-05-24

Similar Documents

Publication Publication Date Title
JP2013177388A (ja) 幹細胞のｍｎｔｆ分化および成長
JP5336384B2 (ja) Ｍｎｔｆペプチドおよびその類似体を用いて神経細胞障害を治療する方法
US20090227521A1 (en) Use of compounds in the treatment of ischemia and neurodegeneration
US20030008273A1 (en) Methods for increasing the survival of neuronal cells
JP5718649B2 (ja) Ｍｎｔｆペプチド組成物およびその使用法
CN113260373B (zh) 用于诱导神经可塑性的方法和组合物
HK1125824B (en) Mntf differentiation and growth of stem cells
Higashida et al. Skin-derived precursors differentiating into dopaminergic neuronal cells in the brains of Parkinson disease model rats
US9402875B2 (en) Amidated dopamine neuron stimulating peptide restoration of mitochondrial activity
US11136362B2 (en) Peptide modulators of specific calcineurin protein-protein interactions
TWI305496B (en) Medical use of secretoneurin for treating brain tissue damages
HK1137623B (en) Methods of treating neuronal disorders using mntf peptides and analogs thereof
HK1151242B (en) Mntf peptide compositions and methods of use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1125824

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1125824

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160420

Termination date: 20201110

CF01 Termination of patent right due to non-payment of annual fee